• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Basic Materials·603155.SS
Share

Xinyaqiang Silicon Chemistry Co.,Ltd Stocks

CN¥ 15.43Last Updated 09.10.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 987.60M

CN¥ 15.43
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Suqian, China, Xinyaqiang Silicon Chemistry Co.,Ltd, founded in 2009, specializes in the production and distribution of organic silicon compounds, specifically methylsilane and phenyl derivatives. Their diverse product portfolio encompasses chemicals such as hexamethyldisiloxane, iodotrimethylsilane, chlorotrimethylsilane, hexamethyldisilane, diethoxydimethylsilane, dimethoxydimethylsilane, phenyltrichlorosilane, dichlorodiphenylsilane, dichlorodimethylsilane, trimethylethoxysilane, methyltrimethoxysilane, and methyltriethoxysilane. Additionally, they provide specialty silazanes and siloxanes, including 1,3-divinyltetramethyldisilazane, 1,3-diethenyl-1,1,3,3-tetramethyldisiloxane, N,1,1,1-tetramethyl-N-(trimethylsilyl)silylamine, 1,1,1,3,3,3-hexamethyldisilazane, and 1,3-Bis(trimethylsilyl)urea.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.10.2026 09:19

Twelve people were killed in an attack on the Riyadh airport

10.10.2026 16:01

What's Important in Small-Cap Stocks: Risks Associated with Webull, Levi's Outlook, and Vaxcyte's Success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

10.10.2026 06:47

Moderna hits four-year high as NYT reports U.S. cancer vaccine effort

10.10.2026 04:58

Palantir shares hit a new high: Barclays followed Goldman in recommending a buy

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026